Doug Arm

Company: EV Therapeutics

Job title: Chief Operating Officer

Bio:

Dr. Doug Arm is a technical executive and independent consultant serving the regenerative medicine, biotechnology, and medical device industries for over 25 years, with expertise in product and process development, manufacturing and operations, preclinical and clinical research, and strategic business development of technologies. He has broad experience leading interdisciplinary teams in the development and manufacturing of technologies including cellular, cell-derived, and tissue therapies from multiple source tissues; bone graft products; and real-time cell and protein processing systems for use in the orthopedics, cardiovascular, plastic & reconstructive surgery, and wound markets. Prior to establishing his consulting business, Dr. Arm served as VP of Product Development and Sr. VP of Operations with Cytori Therapeutics for nearly ten years, with responsibility for research, development, manufacturing, and quality. Prior to Cytori, Dr. Arm spent more than eight years at Interpore Cross International, rising to Director of Biologics Research, and following Interpore’s acquisition by Biomet in an expanded role that included strategic technology evaluation and product development across multiple business units. Before joining Interpore, Dr. Arm completed a post-doctoral fellowship studying mesenchymal stem cells under Dr. Arnold Caplan in the Skeletal Research Center at Case Western Reserve University. He obtained his B.S. in Biomedical Engineering from the Johns Hopkins University, and his Ph.D. in Bioengineering from the University of Washington.

Seminars:

Strategic Development of a Native Extracellular Vesicle Platform Technology for Regenerative Medicine Therapeutic Applications 1:30 pm

EV Therapeutics has broadened our portfolio to include a novel, native EV technology, synergistic with our modified EV therapeutic platform This platform technology has strong MOA data and is supported by positive clinical use data outside the USA Prioritizing this native EV technology enables EV Therapeutics to chart a more rapid path towards clinical trials…Read more

day: Conference Day Two